BACKGROUND AND PURPOSE: Chemokine receptors CXCR1 and CXCR2 may mediate influx of neutrophils in models of acute and chronic inflammation. The potential benefits of oral administration of a CXCR1/2 inhibitor, DF 2162, in adjuvant-induced polyarthritis (AIA) were investigated. EXPERIMENTAL APPROACH: A model of AIA in rats was used to compare the therapeutic effects of the treatment with DF2162, anti-TNF or anti-CINC-1 antibodies on joint inflammation and local production of cytokines and chemokines. KEY RESULTS: DF2162 prevented chemotaxis of rat and human neutrophils induced by chemokines acting on CXCR1/2. DF2162 was orally bioavailable and metabolized to two major metabolites. Only metabolite 1 retained CXCR1/2 blocking activity. Treatment with DF2162 (15 mg kg(-1), twice daily) or metabolite 1, but not metabolite 2, starting on day 10 after arthritis induction diminished histological score, the increase in paw volume, neutrophil influx and local production of TNF, IL-1beta, CCL2 and CCL5. The effects of DF2162 were similar to those of anti-TNF, and more effective than those of anti-CINC-1, antibodies. DF2162 prevented disease progression even when started 13 days after arthritis induction. CONCLUSIONS AND IMPLICATIONS: DF 2162, a novel orally-active non-competitive allosteric inhibitor of CXCR1 and CXCR2, significantly ameliorates AIA in rats, an effect quantitatively and qualitatively similar to those of anti-TNF antibody treatment. These findings highlight the contribution of CXCR2 in the pathophysiology of AIA and suggest that blockade of CXCR1/2 may be a valid therapeutic target for further studies aiming at the development of new drugs for treatment of rheumatoid arthritis.
BACKGROUND AND PURPOSE: Chemokine receptors CXCR1 and CXCR2 may mediate influx of neutrophils in models of acute and chronic inflammation. The potential benefits of oral administration of a CXCR1/2 inhibitor, DF 2162, in adjuvant-induced polyarthritis (AIA) were investigated. EXPERIMENTAL APPROACH: A model of AIA in rats was used to compare the therapeutic effects of the treatment with DF2162, anti-TNF or anti-CINC-1 antibodies on joint inflammation and local production of cytokines and chemokines. KEY RESULTS:DF2162 prevented chemotaxis of rat and human neutrophils induced by chemokines acting on CXCR1/2. DF2162 was orally bioavailable and metabolized to two major metabolites. Only metabolite 1 retained CXCR1/2 blocking activity. Treatment with DF2162 (15 mg kg(-1), twice daily) or metabolite 1, but not metabolite 2, starting on day 10 after arthritis induction diminished histological score, the increase in paw volume, neutrophil influx and local production of TNF, IL-1beta, CCL2 and CCL5. The effects of DF2162 were similar to those of anti-TNF, and more effective than those of anti-CINC-1, antibodies. DF2162 prevented disease progression even when started 13 days after arthritis induction. CONCLUSIONS AND IMPLICATIONS: DF 2162, a novel orally-active non-competitive allosteric inhibitor of CXCR1 and CXCR2, significantly ameliorates AIA in rats, an effect quantitatively and qualitatively similar to those of anti-TNF antibody treatment. These findings highlight the contribution of CXCR2 in the pathophysiology of AIA and suggest that blockade of CXCR1/2 may be a valid therapeutic target for further studies aiming at the development of new drugs for treatment of rheumatoid arthritis.
Authors: P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power Journal: Pharmacol Rev Date: 2000-03 Impact factor: 25.468
Authors: Danielle G Souza; Riccardo Bertini; Angelica T Vieira; Fernando Q Cunha; Steve Poole; Marcello Allegretti; Francesco Colotta; Mauro M Teixeira Journal: Br J Pharmacol Date: 2004-08-09 Impact factor: 8.739
Authors: Shiva Shahrara; Amanda E I Proudfoot; James M Woods; Jeffrey H Ruth; M Asif Amin; Christy C Park; Christian S Haas; Richard M Pope; G Kenneth Haines; Yuan Yuan Zha; Alisa E Koch Journal: Arthritis Rheum Date: 2005-06
Authors: F M Brennan; C O Zachariae; D Chantry; C G Larsen; M Turner; R N Maini; K Matsushima; M Feldmann Journal: Eur J Immunol Date: 1990-09 Impact factor: 5.532
Authors: Michele M Barsante; Ester Roffê; Celina M Yokoro; Wagner L Tafuri; Danielle G Souza; Vanessa Pinho; Maria Salete De A Castro; Mauro M Teixeira Journal: Eur J Pharmacol Date: 2005-06-15 Impact factor: 4.432
Authors: A Nishimura; T Akahoshi; M Takahashi; K Takagishi; M Itoman; H Kondo; Y Takahashi; K Yokoi; N Mukaida; K Matsushima Journal: J Leukoc Biol Date: 1997-10 Impact factor: 4.962
Authors: Robson Alexandre Brochetti; Mayara Peres Leal; Raíssa Rodrigues; Renata Kelly da Palma; Luis Vicente Franco de Oliveira; Anna Carolina Ratto Tempestini Horliana; Amílcar Sabino Damazo; Ana Paula Ligeiro de Oliveira; Rodolfo Paula Vieira; Adriana Lino-Dos-Santos-Franco Journal: Lasers Med Sci Date: 2017-07-16 Impact factor: 3.161
Authors: Carolyn A Lacey; Lauren L Keleher; William J Mitchell; Charles R Brown; Jerod A Skyberg Journal: J Infect Dis Date: 2016-03-06 Impact factor: 5.226
Authors: T M Cunha; M M Barsante; A T Guerrero; W A Verri; S H Ferreira; F M Coelho; R Bertini; C Di Giacinto; M Allegretti; F Q Cunha; M M Teixeira Journal: Br J Pharmacol Date: 2008-03-24 Impact factor: 8.739
Authors: Baomei Wang; Bernd H Zinselmeyer; Herbert A Runnels; Timothy P LaBranche; Phillip A Morton; Daniel Kreisel; Matthias Mack; Cheryl Nickerson-Nutter; Paul M Allen; Mark J Miller Journal: Cell Immunol Date: 2012-08-04 Impact factor: 4.868